AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Grant

Date/time Interval

  • March 23, 2016 - March 22, 2018
  • Total Award Amount

  • 338.00
  • Direct Costs

  • 266.00
  • Sponsor Award Id

  • 9400660000
  • Contributor

  • Alva, Elizabeth   Investigator  
  • Bemrich-Stolz, Christina   Investigator  
  • Bhatia, Smita   Investigator  
  • Friedman, Gregory   Investigator  
  • Galtarossa Xavier, Ana   Investigator  
  • Hilliard, Lee   Investigator  
  • Kutny, Matthew   Investigator  
  • Lebensburger, Jeffrey   Investigator  
  • Whelan, Kimberly   Investigator  
  • Wolfson-Stockman, Julie   Investigator